×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ICAD – icad inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ICAD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/11
10:03 am
icad
SABCS 2024: New Research Assesses iCAD's Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations [Yahoo! Finance]
Low
Report
SABCS 2024: New Research Assesses iCAD's Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations [Yahoo! Finance]
12/11
10:00 am
icad
SABCS 2024: New Research Assesses iCAD’s Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations
Low
Report
SABCS 2024: New Research Assesses iCAD’s Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations
12/4
05:00 pm
icad
CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024
Low
Report
CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024
11/26
01:06 pm
icad
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024 [Yahoo! Finance]
Medium
Report
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024 [Yahoo! Finance]
11/26
01:00 pm
icad
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024
Medium
Report
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024
11/21
03:09 am
icad
iCAD, Inc. (NASDAQ: ICAD) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
iCAD, Inc. (NASDAQ: ICAD) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/14
12:01 am
icad
iCAD, Inc. (NASDAQ: ICAD) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
iCAD, Inc. (NASDAQ: ICAD) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/13
04:01 pm
icad
iCAD Reports Financial Results for Third Quarter Ended September 30, 2024
High
Report
iCAD Reports Financial Results for Third Quarter Ended September 30, 2024
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/23
iCAD Announces Pricing of $12.5 Million Registered Direct Offering
28.5%
2/27 Q4/2019 12/31/2019 EPS -0.100 ZacksConsensus -0.120 ActVsEst 0.020 - Beat 22.1%
2/13 iCAD to Report Fourth Quarter 2019 Financial Results on Thursday, February 27, 2020 12.0%
2/11 First Brain Tumor Treated with Xoft IORT in the United States 8.1%
7/10 SimonMed Imaging Implements the First FDA-Cleared 3D Tomosynthesis Software Using Artificial Intelligence 7.5%
8/1 Q2/2019 6/30/2019 EPS -0.090 ZacksConsensus -0.100 ActVsEst 0.010 - Beat 7.2%
1/15 Form 3 ICAD INC For: Jan 13 Filed by: Klein Michael S 6.9%
9/10 iCAD’s ProFound AI Reader Study Published in Radiology: Artificial Intelligence 6.3%
6/13 iCAD Introduces ProFound AI™ for 2D Mammography in Europe 5.4%
4/28 iCAD Inc (NASDAQ: ICAD) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.3%
2/27 Q4/2019 12/31/2019 EPS -0.100 ZacksConsensus -0.120 ActVsEst 0.020 - Beat 22.1%
2/13 iCAD to Report Fourth Quarter 2019 Financial Results on Thursday, February 27, 2020 12.0%
2/11 First Brain Tumor Treated with Xoft IORT in the United States 8.1%
7/10 SimonMed Imaging Implements the First FDA-Cleared 3D Tomosynthesis Software Using Artificial Intelligence 7.5%
8/1 Q2/2019 6/30/2019 EPS -0.090 ZacksConsensus -0.100 ActVsEst 0.010 - Beat 7.2%
1/15 Form 3 ICAD INC For: Jan 13 Filed by: Klein Michael S 6.9%
9/10 iCAD’s ProFound AI Reader Study Published in Radiology: Artificial Intelligence 6.3%
6/13 iCAD Introduces ProFound AI™ for 2D Mammography in Europe 5.4%
4/28 iCAD Inc (NASDAQ: ICAD) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.3%
TOP News Decliners
3/11
Form 10-K ICAD INC For: Dec 31
-17.2%
8/3 iCAD's (ICAD) CEO Michael Klein on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -11.3%
3/31 iCAD Announces New Credit Facility with Bridge Bank, Increasing Operational Flexibility -10.9%
7/11 iCAD’s ProFound AI™ for 2D Mammography Receives CE Mark Approval -9.3%
10/30 Q3/2019 9/30/2019 EPS -0.100 ZacksConsensus -0.100 ActVsEst 0.000 - In-Line -7.3%
5/15 Form 10-Q ICAD INC For: Mar 31 -5.9%
10/1 iCAD Showcases ProFound AI™ Platform at European Society of Breast Imaging Annual Scientific Meeting in Budapest -5.1%
10/1 iCAD Inc (NASDAQ: ICAD) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -4.2%
3/23 iCAD Launches New Initiatives Leveraging Unique Capabilities of its Robust Product Portfolio to Reduce Health Care System Pressures During the COVID-19 Pandemic -4.0%
6/7 iCAD Inc (NASDAQ: ICAD) was upgraded by analysts at ValuEngine from a "buy" rating to a "strong-buy" rating. -3.9%
8/3 iCAD's (ICAD) CEO Michael Klein on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -11.3%
3/31 iCAD Announces New Credit Facility with Bridge Bank, Increasing Operational Flexibility -10.9%
7/11 iCAD’s ProFound AI™ for 2D Mammography Receives CE Mark Approval -9.3%
10/30 Q3/2019 9/30/2019 EPS -0.100 ZacksConsensus -0.100 ActVsEst 0.000 - In-Line -7.3%
5/15 Form 10-Q ICAD INC For: Mar 31 -5.9%
10/1 iCAD Showcases ProFound AI™ Platform at European Society of Breast Imaging Annual Scientific Meeting in Budapest -5.1%
10/1 iCAD Inc (NASDAQ: ICAD) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -4.2%
3/23 iCAD Launches New Initiatives Leveraging Unique Capabilities of its Robust Product Portfolio to Reduce Health Care System Pressures During the COVID-19 Pandemic -4.0%
6/7 iCAD Inc (NASDAQ: ICAD) was upgraded by analysts at ValuEngine from a "buy" rating to a "strong-buy" rating. -3.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: